NYSE$CVSA

Covista Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Adtalem reported robust revenue and earnings per share growth, driven by enrollment increases and solid performance in Financial Services.

Adtalem Global Education reported a 5.4% increase in revenue to $268.2 million and a diluted EPS of $0.38. Excluding special items, diluted EPS from continuing operations was $0.78, a 129% increase. The company experienced double-digit enrollment growth in Chamberlain University and solid single-digit growth across its medical and veterinary schools. COVID-19 impacted revenue and EPS by approximately $14 million and $0.11, respectively.

  • Revenue increased by 5.4% compared to the prior year.
  • New and total student enrollment increased by 12.2% and 10.8%, respectively.
  • Diluted earnings per share was $0.38, with diluted earnings per share from continuing operations excluding special items at $0.78, a 129% increase.
  • Operating income was $36.7 million, with operating income excluding special items at $54.4 million, a 97.7% increase.

Headline financials

Total Revenue

$268M

Previous: $255M+5.4%
EPS (adj)

$0.78

Previous: $0.34+129.4%
Capital Expenditures

-$14.4M

Previous: -$10.4M-38.4%
Free Cash Flow

$5.49M

Previous: $3.93M+39.8%
Net Income

$19.9M

Previous: $14.4M+38.8%
Operating Income

$45.9M

Previous: $20.9M+119.2%
Gross Profit

$155M

Previous: $127M+22.1%
Cash & Equivalents

$561M

Previous: $121M+363.5%
Total Assets

$2.33B

Previous: $2.46B-5.3%
Stock-Based Comp

$4M

Previous: $5.22M-23.3%

Revenue & EPS history

Adtalem · Revenue · Quarterly

$268M

Q1 2021+5.4%vs Q1 2020
Beat estimate in 8 of 16 quarters(50%)
ActualEstimate

Revenue by segment

Adtalem · $369M total across 3 segments · Q1 2024

  • Chamberlain
    $143M+5.3%
  • Walden
    $142M+8.2%
  • Medical and Veterinary
    $84.6M-4.1%

Forward guidance

Adtalem expects revenue growth of 5-7% and growth for diluted earnings per share from continuing operations excluding special items of 25-30% for the full fiscal year 2021.

Tailwinds

  • Revenue growth of 5-7% is expected.
  • Diluted earnings per share from continuing operations excluding special items is expected to grow 25-30%.
  • Strong enrollment trends in Medical and Healthcare.
  • Solid performance in Financial Services.
  • Strategic investments driving growth.

Headwinds

  • Forward-looking statements are subject to risks and uncertainties.
  • COVID-19 pandemic may continue to impact results.
  • Restructuring expenses may impact earnings.
  • Business acquisition and integration expenses may impact earnings.
  • Potential impact of any business or asset acquisitions or dispositions during the remainder of fiscal year 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.7%

Avg return

Earnings day

-0.3%

Avg return

5 days after

+0.7%

Avg return

30 days after

43%

29 / 67 earnings

Positive

+22.8%

Q1 2013

Best reaction

-33.2%

Q1 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026+13.2%+10.2%+8.0%
Q2 2026-7.8%-14.2%-15.5%
Q1 2026-33.2%-31.2%-34.7%
Q3 2025+16.4%+11.9%+10.7%
Q2 2025+4.6%+7.5%-0.1%
Q1 2025+12.0%+8.7%+23.8%
Q4 2024-7.3%-2.1%-2.2%
Q3 2024+18.9%+24.8%+27.5%
Q2 2024-13.9%-17.5%-15.6%
Q1 2024+12.5%+16.6%+29.4%
Q4 2023-1.1%-4.0%-0.8%
Q3 2023+4.5%+2.0%+2.4%
Q2 2023+13.7%+3.1%+2.2%
Q1 2023+2.4%+6.9%-2.1%
Q4 2022-3.1%-2.6%-2.8%
Q3 2022+6.4%+10.9%+17.5%
Q2 2022-12.7%-16.0%-15.2%
Q1 2022-12.9%-6.0%-16.6%
Q4 2021+1.3%+0.3%+11.8%
Q3 2021-6.9%-8.3%-1.3%
Q2 2021+0.1%+0.9%-2.8%
Q1 2021+3.7%+11.0%+16.6%
Q4 2020-4.4%-6.5%-25.9%
Q3 2020+3.7%+9.8%+11.5%
Q2 2020+3.1%-3.0%-14.9%
Q1 2020-19.2%-16.8%-7.8%
Q4 2019-12.5%-14.6%-20.9%
Q3 2019-7.6%-9.0%-11.4%
Q2 2019-3.3%-3.6%-4.1%
Q1 2019+4.3%+10.7%+14.0%
Q4 2018-15.8%-13.5%-20.0%
Q3 2018-5.7%-3.0%+1.4%
Q2 2018+7.1%+3.7%+12.3%
Q1 2018-2.7%+1.1%+9.7%
Q4 2017+4.3%+4.0%+8.1%
Q3 2017-0.8%+5.0%+0.5%
Q2 2017-0.5%-3.0%+0.2%
Q1 2017+1.8%+1.5%+31.5%
Q4 2016+17.7%+11.8%+4.3%
Q3 2016+17.3%
Q2 2016-14.2%
Q1 2016-2.3%
Q4 2015-7.7%
Q3 2015-15.9%
Q2 2015-17.9%
Q1 2015+0.8%
Q4 2014-3.2%
Q3 2014+13.0%
Q2 2014-2.6%
Q1 2014+6.2%
Q4 2013-9.5%
Q3 2013-17.6%
Q2 2013+19.1%
Q1 2013+22.8%
Q4 2009-2.2%
Q4 2012-2.3%
Q3 2012-0.4%
Q2 2012-8.5%
Q1 2012-0.8%
Q4 2011+4.7%
Q3 2011-1.4%
Q3 2010-1.4%
Q2 2010+0.0%
Q2 2011+0.0%
Q4 2010-1.1%
Q1 2010-1.1%
Q1 2011-1.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro